This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 31 open trials
NEOD001 in AL amyloidosis
The aim of this study is to determine the long-term safety and effectiveness of the drug NEOD001 in patients with AL amyloidosis.
NEOD001 is a monoclonal antibody that targets light chain amyloid deposits.
Queen Elizabeth Hospital, Birmingham;
Royal Free Hospital, London
Who can enter the study?:
Patients with AL amyloidosis who previously took part in the NEOD001-201 (PRONTO) study.
NEOD001 is given intravenously (into the vein) every 28 days.
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
(for Medical Professionals):
This is a Phase IIb, open-label extension trial of AL amyloidosis patients who completed study NEOD001-201.
For more information, click here